On Jul. 24, 2018, Hangzhou Sumgen Biotech Co., Ltd. (hereinafter “Sumgen”) announced that IND (Investigational New Drug) application of their proprietary recombinant anti-PD-1 fully human monoclonal antibody injection was filed to CDE (Center for Drug Evaluation in China) of NMPA (China National Medical Products Administration) (acceptance number: CXSL1800084 G).
Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044
